Subscribe
race-1-
OSTILL / SHUTTERSTOCK.COM
3 March 2015AmericasGunars Gaikis

Generics in Canada: The race for market exclusivity

The Supreme Court of Canada has tentatively set April 20, 2015 as the date for the hearing of Sanofi’s appeal against a court’s decision that the company is liable for generic drug maker Apotex’s lost sales of ramipril based on section 8 of the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.

More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact